# Annovis Bio (ANVS) — Overview

ANVS · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/anvs

## Price

Last close $1.05 on Oct 15, 2026. 52-week range $1.02 – $5.10.

## Company profile

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

## Frequently Asked Questions

### How do I buy stock in Annovis Bio (ANVS)?

ANVS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

## Similar Stocks

- [ALXO](https://www.lighthorse.io/tickers/alxo) — ALX Oncology Holdings Inc. - Common Stock

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).